Book summary “Bad Science”: summary

Introduction

You are constantly surrounded by conflicting health claims. Medical advice fills news feeds, alternative therapies promise miraculous cures, and pharmaceutical companies advertise breakthrough treatments. You find it difficult to separate genuine medical science from commercial propaganda and statistical manipulation. When every newspaper headline contradicts the last, you struggle to know whom you can trust.

Ben Goldacre argues in Bad Science that modern medicine is systematically distorted by hidden trial data, misleading statistics, and aggressive commercial marketing that prioritizes profit over patient health. You learn that the core problem is not just eccentric fringe gurus selling useless supplements. The deeper crisis lies within mainstream pharmaceutical research, where powerful companies routinely conceal negative results, corrupt academic publications, and manipulate regulatory bodies.

The book takes you behind the scenes of clinical research to expose how evidence is manufactured and distorted. You discover how industry sponsors design rigged trials, bury unfavorable outcomes, and use marketing departments disguised as independent scientific experts to influence doctors. The investigation moves from laboratory methodologies to global regulatory failures, showing how the entire infrastructure of medicine has been compromised by commercial interests.

This text answers several critical questions about the state of modern healthcare.

• How do pharmaceutical companies hide negative clinical trial results from doctors and patients?
• Why do regulatory agencies approve drugs without proving they beat older treatments?
• How do marketing campaigns invent new diseases and exaggerate the benefits of medications?
• What practical reforms can restore honesty and transparency to medical research?

1. The Scale of Missing Data

Withholding negative clinical trial results is the most destructive problem in medicine, making true treatment effects impossible to know.

Why we summarise data

You rely on systematic reviews and meta-analyses to make sense of medical research. These tools gather all available trials on a treatment to give you a single reliable answer. If the underlying data is flawed, your conclusions will be wrong.

Industry-funded clinical trials are significantly more likely to produce positive, flattering results for the sponsor's drug than independently-funded trials. Commercial sponsors have a financial stake in positive outcomes. This skew occurs through selective publication and various design biases, systematically distorting the medical literature.

A 2010 study of 500 trials across five major drug classes found that 85 per cent of industry-funded studies were positive compared to only 50 per cent of government-funded trials. Research about research reveals a consistent pattern:

• 192 trials explored statin benefits;
• 28 per cent win rate for competing drugs against the sponsor's drug.

Why missing data matters

Withholding negative trial data leaves doctors and patients completely misled, causing them to prescribe ineffective or harmful treatments under the false impression they are safe. When only positive trials are published, a drug appears effective and safe in the academic literature. When unpublished negative data is brought to light, it reveals that the drug performs no better than a placebo and carries higher rates of adverse side effects and dropouts.

Ben Goldacre prescribed reboxetine based on published positive trials, only to learn later that unpublished data covering far more patients showed it was no better than a sugar pill and caused more patients to drop out due to side effects.

In October 2010 researchers brought together all reboxetine trials. The single published positive placebo trial involved 254 patients. At the same time, 1,657 patients' worth of data was left unpublished for competitor comparisons, alongside 507 patients in published comparative studies.

How much data is missing?

Analysis of regulator archives demonstrates that drug companies systematically bury negative trials while publishing positive ones, inverting the real ratio of success and failure. By comparing US Food and Drug Administration submission records with published literature, researchers showed that a balanced split of positive and negative trials becomes overwhelmingly positive in academic journals due to selective non-publication and spin.

A 2008 study of 74 studies in total representing 12,500 patients found an even split of 38 positive trials and 36 negative trials submitted to the FDA, yet academic journals published 37 of the positive trials and only 3 of the negative ones.

2. Institutional Failures in Transparency

Universities, ethics committees, and regulators routinely permit industry sponsors to impose gagging clauses and conceal complete study reports.

How ethics committees and universities have failed us

University administrators and ethics committees routinely permit industry sponsors to impose gagging clauses and retain complete control over clinical trial data. Contracts between academic institutions and pharmaceutical companies frequently grant sponsors the right to see data as it accumulates, stop trials early, or forbid researchers from publishing or discussing findings without sponsor approval. These severe limitations on academic freedom are concealed from published papers.

A study of clinical trials approved in Copenhagen found that 44 trials were overwhelmingly sponsored by the pharmaceutical industry at 98 per cent. Sixteen of those trials allowed sponsors to see data as it accumulates, and 16 trials allowed sponsors to stop the trial at any time. Half of the trials gave the sponsor outright ownership of the data or final approval rights over publication.

Sheffield University lecturer Aubrey Blumsohn was offered £145,000 in a gagging clause settlement after attempting to publish independent safety data.

How regulators and journals have failed us

Regulatory bodies, journal editors, and governments have introduced superficial transparency initiatives that failed to curb publication bias while providing false reassurance. Clinical trial registries and journal editor pledges intended to mandate pre-registration and reporting have been widely ignored, poorly enforced, or kept entirely secret. Companies routinely flout mandatory reporting laws because statutory fines are negligible compared to drug revenues.

• The FDA Amendment Act 2007 established a fine of $10,000 a day for non-compliance, up to a maximum of $3.5 million a year.
• The European Medicines Agency created the EudraCT register containing 30,000 trials, but kept its contents entirely secret.
• EudraPharm still had 10,000 trials missing as of summer 2012.

Blood from a stone: trying to get data from regulators

Medicines regulators routinely obstruct independent scientists from accessing complete clinical study reports, citing commercial confidentiality over public health. When independent research groups request full trial documentation from regulatory agencies like the European Medicines Agency, they face years of bureaucratic obstruction, shifting legal excuses regarding intellectual property, and refusals based on commercial secrecy.

Researchers from the Nordic Cochrane Centre fought a three-and-a-half-year battle with the European Medicines Agency to obtain full study reports for diet drugs like orlistat and rimonabant. The initial request was filed to the European Medicines Agency in June 2007, and the final Ombudsman ruling of maladministration was published in November 2010. The Danish Medical Authority later handed over 56 study reports to Cochrane.

3. From Laboratory to Global Trials

New drugs are typically developed by copying the mechanisms of existing medications to target specific biological pathways, which is much safer and more predictable than inventing entirely novel mechanisms. Researchers look for molecules that affect biological targets, such as enzymes. Common pain-relief drugs like aspirin, paracetamol, ibuprofen, ketoprofen, and fenoprofen all work by inhibiting the cyclooxygenase enzyme.

Drug companies outsource clinical trials to developing countries and rely on vulnerable populations while weakening ethical standards.

Phase 1 trials rely heavily on economically vulnerable populations who participate for financial compensation, creating an unregulated mild torture economy where participants endure risks for income. Early trials test escalating doses on small groups of healthy volunteers. Because participation offers significant daily pay relative to alternatives, low-income individuals, homeless people, and students often act as professional guinea pigs, facing power dynamics that discourage complaints or withdrawals.

In 1996, Eli Lilly recruited homeless alcoholics from a local shelter for trials, with a director stating these individuals wanted to help society. Only 20 per cent of drugs entering phase 1 trials go on to be approved and marketed. Typical payment for phase 1 participants ranges from $200 to $400 a day.

CROs and trials around the world

Pharmaceutical companies increasingly outsource clinical trials to Clinical Research Organizations (CROs) operating in developing countries to drastically reduce costs and accelerate timelines. CROs manage thousands of trials globally on behalf of the pharmaceutical industry.

A former chief executive of GSK explained that running a trial costs $30,000 per patient in the US compared to $3,000 in Romania, prompting companies to shift operations to low-cost countries. By 2010, global revenue for CROs reached $20 billion, representing about a third of pharma R&D spending. In 2008, CROs ran 9,000 trials with over two million participants across 115 countries.

• Annual growth rates reached 20 per cent in India, 47 per cent in China, and 27 per cent in Argentina, alongside falling rates in the US and UK.

Ethical violations in developing country trials can occur when experimental treatments are tested on vulnerable populations without proper informed consent or when local standard care is withheld. During a 1996 meningitis epidemic in Kano, Nigeria, Pfizer tested the experimental antibiotic Trovan. Eleven children died during the study, and subsequent investigations revealed violations of Nigerian law and ethical codes. WikiLeaks cables later revealed Pfizer hired investigators to pressure the Nigerian attorney general to drop the lawsuit, culminating in a 2009 out-of-court settlement of $75 million.

Regulatory bodies have sometimes weakened ethical standards for foreign-conducted trials by replacing moral principles with procedural guidelines that lack key patient protections. In 2008, the FDA changed its requirement for foreign trial evidence from the Declaration of Helsinki to Good Clinical Practice (GCP) guidelines. Unlike Helsinki, the GCP guidelines do not mandate that research benefit the local population, ensure post-trial access to treatment, or strictly restrict the use of dummy placebos when effective treatments exist.

4. Bad Regulators and Low Standards

Drug regulators suffer from regulatory capture and approve medications without requiring proof that they outperform existing treatments.

You might assume that government agencies rigorously protect you from ineffective medicine. In reality, drug regulators often suffer from regulatory capture, promoting the interests of the pharmaceutical industry they are supposed to monitor. Officials socialize with industry representatives and share oral traditions on how to bypass rules. A revolving door operates as officials leave for lucrative positions in drug companies, creating subtle psychological shifts and conflicts of interest.

Thomas Lonngren stepped down as executive director of the European Medicines Agency and gave four days' notice before starting as a private consultant to the pharmaceutical industry in 2010. By then, 55 per cent of hospital doctors and 37 per cent of GPs had never heard of the Medicines and Healthcare products Regulatory Agency.

Approving a drug

Regulators frequently approve new drugs without requiring proof that they are better than existing treatments, only demanding they beat a placebo. This better than nothing standard is ethically problematic because it exposes real patients to dummy pills when effective treatments already exist. It also fails to answer the practical question doctors and patients care about regarding superiority. A 2011 study showed that a full third of 197 new drugs approved by the FDA between 2000 and 2010 had no evidence comparing them with the best currently available treatment, and only 70 per cent had data to show they were better than other treatments.

Surrogate outcomes

Drugs are often approved based on surrogate outcomes, such as blood test results, rather than real-world endpoints like heart attacks or death. While surrogate outcomes provide quick short-term data, they often fail to translate into real-life benefits and have historically sometimes led to increased mortality rates.

Well over a hundred thousand people died as a result of ineffective anti-arrhythmic drugs. The Cardiac Arrhythmia Suppression Trial tested these drugs and found they successfully prevented abnormal heart rhythms, but a proper trial measuring death had to be stopped early because the drugs dramatically increased mortality.

Comparative effectiveness research

Pharmaceutical companies maximize profits by producing copycat drugs or slightly modified versions of existing molecules as patents expire. Without regulatory requirements to prove superiority over older treatments, companies launch me-too drugs or single enantiomer me-again preparations that offer no significant clinical benefits while driving up healthcare costs.

AstraZeneca launched esomeprazole, the single left-handed enantiomer of omeprazole, just as omeprazole's patent expired, maintaining billions in revenue despite no dramatic therapeutic advantage. This followed omeprazole making $5 billion every year, and AstraZeneca spent $260 million on US ads for esomeprazole in 2003.

Because regulators do not require comparisons against the best available treatments, governments must step in to fund large-scale trials that measure real-world clinical outcomes and identify superior, cheaper alternatives. The ALLHAT trial compared an old, cheap blood-pressure pill against an expensive new one and found the old drug was much better at preventing heart attacks, generating massive savings. The trial cost $125 million, started in 1994, and finished in 2002.

5. Methodological Flaws in Trials

Researchers manipulate trial designs through unrepresentative ideal patients, rubbish comparators, and switched primary outcomes to manufacture positive results.

Clinical trials often test drugs on freakishly ideal patients who are atypical of the real world. This distorts cost-effectiveness estimates and exaggerates benefits. Real patients are complex, older, and take multiple medications or have comorbid conditions. Trials usually exclude them in favor of young, single-diagnosis participants. This can overestimate benefits or even reverse the risk-benefit balance. Real-world costs per avoided medical event become much higher than predicted.

A 2011 Finnish study found that out of 7,411 hip fracture patients, only 1,072 met the strict age, sex, and health criteria used in bisphosphonate trials. The trial data applied to just one in seven real patients.

Researchers can make a new drug look artificially effective by comparing it against an inferior competitor. They might use an older drug or a competitor given at an excessively high dose. Comparing a modern drug against a known poor competitor induces excessive side effects in the comparator group. This makes the new treatment appear vastly superior.

In antipsychotic research, trials compared new atypical antipsychotics against the old drug haloperidol at a harsh 20mg daily dose. Other trials used risperidone at a high 8mg dose, deliberately generating more side effects in the comparator arm.

Bundling multiple disparate endpoints into a single composite outcome can manufacture false positive results. Researchers also switch pre-specified primary outcomes after seeing the data. They make an ineffective drug look successful by grouping trivial improvements with major outcomes. Alternatively, they quietly change their primary outcome to whichever metric yielded a statistically significant result.

The UKPDS diabetes trial reported a 12 per cent reduction in a massive composite outcome. Re-analysis showed this was almost entirely driven by a reduction in minor laser treatments for eye blood vessels. It did not show reductions in death or blindness.

Seeding trials are disguised marketing campaigns that enrol large numbers of doctors and small numbers of patients. Their primary purpose is influencing prescribing habits rather than answering clinical questions. Drug companies run poorly designed trials across vast networks of community clinics under the guise of scientific research. The real goal is familiarising physicians with the drug and tracking their subsequent prescription volumes. This exposes patients to undocumented risks without ethical transparency.

Internal documents released during litigation revealed that Merck's ADVANTAGE trial for Vioxx and the STEPS trial for Neurontin were executed to drive sales. The ADVANTAGE trial targeted 5,000 patients and recruited 600 participating doctors. The STEPS trial involved 2,759 patients and recorded 11 deaths.

Presenting trial findings using relative risk reduction rather than absolute risk reduction makes modest treatments appear dramatically effective. Publishers also use text-based spin in abstracts. Expressing risk reductions in relative terms inflates trivial absolute differences into impressive figures. Combined with editorial spin in academic abstracts and industry-funded reviews, this misinforms clinicians and the public.

Coverage of the Jupiter trial for rosuvastatin widely trumpeted a 54 per cent reduction in heart attacks in newspapers. This masked the fact that the absolute risk reduction was tiny because the baseline risk in low-risk patients was exceptionally low. The rate dropped from 0.37 events per one hundred person years on placebo to 0.17 on rosuvastatin.

6. Bigger, Simpler Trials

Massive clinical questions could be answered rapidly if standard medical care systematically incorporated large-scale randomised trials. You can see this potential in everyday practice where fundamental treatment choices remain unresolved.

Routine medical software can embed large-scale pragmatic trials directly into everyday prescribing to answer critical clinical questions cheaply.

A BMJ paper highlighted that medical management of stroke could be transformed in the time it takes to grow a sunflower. Entering every stroke patient in the world into a randomised trial comparing best treatments would recruit enough participants in twenty-four hours to determine the best approach.

Embedded GP trials

Routine general practice software can be adapted to embed cheap, unobtrusive randomised trials directly into everyday prescribing workflows. You do not need complex trial infrastructure when electronic medical records already capture prescriptions and health outcomes.

The author helped set up a trial where doctors prescribing statins encounter an extra screen. This button randomly assigns the patient to one of two common statins, automatically gathering all outcomes from computerised medical notes without extra paperwork. A pilot study comparing atorvastatin and simvastatin adds a single prompt to GP prescribing software to randomise patients and track outcomes automatically. Setting up the first trial and building the reusable software platform cost £500,000.

Observational data can be dangerously misleading because patients receiving different treatments are often fundamentally unalike due to hidden biases. Researchers relied on observational data showing women taking hormone replacement therapy lived longer, healthier lives. They missed that HRT users were wealthier and more active, whereas a subsequent randomised trial proved HRT actually increases heart risks.

Regulatory double standards

A bizarre regulatory paradox subjects doctors attempting to generate knowledge through randomisation to intense red tape while permitting arbitrary treatment choices. You can choose freely between standard treatments without paperwork, but formal randomisation triggers enormous hurdles.

The CRASH trial on head injuries faced severe ethics committee battles over randomising unconscious patients to steroids or no-steroids. The trial ultimately revealed that steroids caused two and a half extra deaths per hundred patients due to delayed discovery.

7. Marketing and Promotion

Pharmaceutical companies spend vastly more on marketing than on research, utilizing ghostwriters, drug reps, and disease-mongering to alter prescribing habits.

The pharmaceutical industry overall spends about twice as much on marketing and promotion as it does on research and development. This undermines the justification that high prices of new drugs, such as AIDS medications in developing countries, are necessary to fund future R&D. The US alone sees $60 billion spent annually on medicines marketing.

Prescribing Patterns and Waste

Doctors frequently prescribe expensive brand-name me-too drugs instead of equally effective, cheaper off-patent alternatives. This wastes billions of pounds in public healthcare funds. Academics calculated that billions are wasted annually by failing to switch patients to off-patent generic equivalents that are clinically indistinguishable.

In 2009, despite major national switching programs, there were still three million prescriptions for atorvastatin instead of the cheaper off-patent simvastatin. This cost the NHS an unnecessary £165 million a year. The UK wastes £1 billion every year by using branded me-too drugs instead of available off-patent alternatives out of a £9 billion NHS annual spending on drugs.

Adverts to patients

Direct-to-consumer drug advertising distorts prescribing behavior by convincing healthy people that normal human experiences are pathological conditions requiring medication. Studies show that patients who request specific advertised drugs are twice as likely to receive them, even when presenting with normal life stressors like adjustment disorder.

Trained actor-patients presenting with normal feelings of low mood after a bad life event were given prescriptions for specific requested antidepressant drugs in 50 per cent of cases. When rules were relaxed in 1997, the pharmaceutical industry saw its annual advertising budget rise from $200 million to $3 billion.

More than molecules

Drug companies engage in disease-mongering by widening diagnostic boundaries and inventing new diseases to turn healthy people into consumers of specific molecules. Normal human variations and everyday discomforts are labeled as medical dysfunctions under the guise of raising health awareness.

A website launched by WebMD and funded by Eli Lilly provided a depression checklist where answering no to every single question still resulted in a warning message stating the user may be at risk for major depression. A 1999 survey subsequently linked to Pfizer consulting work led to 43 per cent of all women being labeled as having Female Sexual Dysfunction, supported by 1,691 citations.

Patient groups

Patient advocacy groups heavily funded by pharmaceutical companies often echo industry lobbying objectives while failing to criticize drug pricing policies. Two thirds of patient groups working with the European Medicines Agency receive industry funding, with an average donation of €321,230 in 2008.

Major patient groups like the National Rheumatoid Arthritis Society and the National Kidney Federation attacked NICE for rejecting expensive drugs as barbaric or a nail in the coffin. They failed to criticize their industry funders for charging tens of thousands of pounds for those treatments. The National Kidney Federation operates on an annual budget of £300,000, half of which comes from the pharmaceutical industry.

Drug reps

Sales representatives visiting doctors in their offices measurably distort prescribing patterns and increase healthcare costs, despite doctors naively believing they are immune to influence. A US study reported regular contact with drug reps among 96 per cent of nurse prescribers.

A classic hospital study showed that doctors who requested new drugs to be added to their hospital formulary were thirteen times more likely to have met drug reps and nineteen times more likely to have accepted direct money from drug companies. Twenty-nine systematic review studies have looked at the impact of drug rep visits.

Ghostwriters

Commercial medical writers employed by pharmaceutical companies covertly draft academic papers and reviews. They place independent academics' names at the top to create a false illusion of scientific independence. A 2011 study identified ghost authorship in 8 per cent of all articles in six leading medical journals. Furthermore, 75 per cent of industry-funded trials in two Danish cities showed evidence of ghost authorship.

During a court case involving the antipsychotic drug Zyprexa, internal emails revealed that a promotional paper published in Progress in Neurology and Psychiatry was ghostwritten by manufacturer Eli Lilly and then assigned to consultant psychiatrist Dr. Peter Haddad.

Pharma's medical school

Continuing medical education for qualified doctors is largely funded and organized by pharmaceutical companies, serving as a disguised promotional platform. In 2008, three-quarters of all continuing medical education activity in France was paid for by the pharmaceutical industry, alongside 760,000 hours of continuing medical education offered across 100,000 activities in the US.

Researchers analyzing mystery shoppers attending industry-sponsored continuing medical education on blood-pressure drugs found that the sponsor's drug received three times as many positive mentions as negative ones. Competitor drugs received a much harsher critique.

What does it mean to take money?

Financial ties between medical researchers and drug companies strongly correlate with pro-industry conclusions in published commentaries, reviews, and clinical evaluations. An analysis of papers discussing the safety of the diabetes drug rosiglitazone found that authors who concluded the drug was safe were 3.38 times more likely to have a financial conflict of interest with its manufacturer.

ProPublica's Dollars for Docs campaign aggregated $750 million in industry payments to US doctors. In 2010, Pfizer spent $3,065 on food for a single doctor in West Hollywood.

8. Better Data and Reform

Achieving true reform requires a historical amnesty, full public disclosure of all trial data, and rigorous medical school training on industry marketing.

Afterword: Better Data

Missing clinical trial data is the most destructive problem in medicine. Withholding negative results makes it impossible to know true treatment effects. Half of all clinical trials go unpublished, according to the current best estimate from systematic reviews.

While marketing distortions can be bypassed by consulting systematic reviews, missing data affects everyone equally. No expert has access to hidden trials. Individual shameful cases like paroxetine, Tamiflu, or Orlistat illustrate how ugly the consequences of hidden data can be.

Clearing the decks

Real reform requires a complete historical amnesty where pharmaceutical companies publicly disclose all hidden trial data and covertly ghostwritten papers. Medicine relies on an evidence base accumulated over decades, and promising to behave better in the future is insufficient. Every hidden trial and rigged academic paper must be identified to prevent ongoing patient harm.

Commercial medical writers and drug companies have privately admitted that ghostwriting was rife. GlaxoSmithKline received a $3 billion fine for civil and criminal fraud in July 2012. Corporate whistleblowers shared roughly $600 million of this settlement. During the covered period, sales of rosiglitazone reached $10 billion, paroxetine brought in $12 billion, and Wellbutrin $6 billion.

Patient and whistleblower action

Patients and public groups possess significant leverage and can demand transparency. You can ask your doctor about industry hospitality. You can press patient-advocacy groups to demand clear disclosures from drug companies regarding any withheld data on your specific diseases.

If you participate in clinical trials, you should ask for written guarantees. Ensure you secure commitments for public registration, reporting within one year, and access to the final results report. Only one in five trials report within a year according to current estimates under FDA rules.

You can protect the medical profession by supporting concrete institutional changes:

• demand formal medical school training on industry marketing techniques;
• require full public disclosure of all clinical trial data;
• encourage industry insiders to act as whistleblowers;
• support legal protections for data dumps.

Modern healthcare operates within a distorted ecosystem where commercial priorities routinely override patient welfare. You navigate a landscape where hidden negative trials, manipulated methodologies, and pervasive marketing systematically inflate the apparent benefits of treatments while concealing their harms. Regulators, academic institutions, and professional bodies often fail to enforce basic transparency, leaving you vulnerable to exaggerated claims and substandard care. Fixing this systemic failure requires you to adopt a critical stance toward all medical information, demanding rigorous evidence and open access to complete data sets. You can protect your health and support genuine scientific progress by following a few practical rules.

1. Demand access to complete clinical trial data before accepting the claims made by commercial manufacturers or mainstream media reports.
2. Question every promotional statistic by looking for absolute risk reductions and real-world numbers rather than relative percentages alone.
3. Reject the false dichotomy between conventional and alternative medicine, insisting that every treatment substantiate its claims through properly randomized and blinded trials.
4. Support the establishment of routine pragmatic trials embedded within everyday clinical practice to generate reliable and unbiased evidence.
5. Scrutinize the financial relationships of researchers, journals, and professional organizations to identify potential conflicts of interest.
6. Advocate for radical institutional reform, including mandatory public registries for all clinical trials and comprehensive historical amnesties for missing data.
7. Educate yourself and others to recognize the tactics of disease-mongering, ghostwriting, and aggressive marketing deployed by the pharmaceutical industry.

10 Key Ideas

1. Withholding negative clinical trial results is the most destructive problem in medicine, making true treatment effects impossible to know.
2. University administrators and ethics committees routinely permit industry sponsors to impose gagging clauses and retain complete control over clinical trial data.
3. Drug regulators suffer from regulatory capture and approve medications without requiring proof that they outperform existing treatments.
4. Drugs are often approved based on surrogate outcomes, such as blood test results, rather than real-world endpoints like heart attacks or death.
5. Clinical trials often test drugs on freakishly ideal patients who are atypical of the real world, which distorts cost-effectiveness estimates and exaggerates benefits.
6. Seeding trials are disguised marketing campaigns that enrol large numbers of doctors and small numbers of patients to influence prescribing habits rather than answer clinical questions.
7. Pharmaceutical companies spend vastly more on marketing than on research, utilizing ghostwriters, drug reps, and disease-mongering to alter prescribing habits.
8. GlaxoSmithKline received a $3 billion fine for civil and criminal fraud in July 2012, highlighting the massive financial penalties associated with fraudulent corporate practices.
9. You rely on systematic reviews and meta-analyses to make sense of medical research, but if the underlying data is flawed, your conclusions will be wrong.
10. Achieving true reform requires a historical amnesty, full public disclosure of all trial data, and rigorous medical school training on industry marketing.